NASDAQ:HSKA Heska (HSKA) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$119.99▼$119.9950-Day Range$115.55▼$119.9952-Week Range$57.83▼$120.03VolumeN/AAverage Volume241,932 shsMarket Capitalization$1.31 billionP/E RatioN/ADividend YieldN/APrice Target$137.25 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Heska (NASDAQ:HSKA) StockHeska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.Read More HSKA Stock News HeadlinesJune 8, 2023 | markets.businessinsider.comWhy eXp World Holdings Shares Are Rising ThursdayMay 19, 2023 | msn.comHeska Earnings Perspective: Return On Capital EmployedSeptember 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.May 11, 2023 | businesswire.comHESKA CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Heska ...May 9, 2023 | finance.yahoo.comStrong Fourth Quarter Results Supported Heska Corporation (HSKA) in Q1May 5, 2023 | finance.yahoo.comHeska (HSKA) Q1 Earnings and Revenues Lag EstimatesMay 5, 2023 | finance.yahoo.comHeska Corporation Reports First Quarter 2023 ResultsApril 21, 2023 | finance.yahoo.comHeska Announces Annual Meeting of Stockholders on May 3, 2023September 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.April 4, 2023 | finance.yahoo.comThe three-year returns have been strong for Heska (NASDAQ:HSKA) shareholders despite underlying losses increasingApril 3, 2023 | finance.yahoo.comWhy Heska Stock Is On Fire TodayApril 3, 2023 | finance.yahoo.comMars to Acquire Heska, Global Provider of Advanced Veterinary Diagnostic and Specialty SolutionsMarch 1, 2023 | finance.yahoo.comHeska (HSKA) Q4 Earnings and Revenues Surpass EstimatesMarch 1, 2023 | finance.yahoo.comHeska Full Year 2022 Earnings: EPS Misses ExpectationsMarch 1, 2023 | finance.yahoo.comAt US$81.43, Is It Time To Put Heska Corporation (NASDAQ:HSKA) On Your Watch List?February 28, 2023 | finance.yahoo.comHeska Corporation Reports Fourth Quarter and Full Year 2022 ResultsFebruary 23, 2023 | finance.yahoo.comHeska to Present at Three Upcoming Institutional Investor ConferencesFebruary 13, 2023 | finance.yahoo.comHeska (HSKA) Moves to Buy: Rationale Behind the UpgradeFebruary 8, 2023 | finance.yahoo.comHeska Fourth Quarter and Full Year 2022 Financial Results and Earnings Call Scheduled for February 28, 2023January 18, 2023 | finance.yahoo.comIs There An Opportunity With Heska Corporation's (NASDAQ:HSKA) 50% Undervaluation?January 12, 2023 | gurufocus.comHeska Corp's CEO Loads Up on Shares After 70% NosediveJanuary 11, 2023 | finance.yahoo.comHeska (HSKA) Moves 9.0% Higher: Will This Strength Last?January 3, 2023 | finance.yahoo.comHeska Corporation Completes Acquisition of LightDeck DiagnosticsDecember 23, 2022 | finance.yahoo.comHeska to Participate in the 41st J.P. Morgan Annual Healthcare ConferenceNovember 8, 2022 | finance.yahoo.comHeska Corporation Reports Third Quarter 2022 ResultsNovember 8, 2022 | finance.yahoo.comHeska (HSKA) Q3 Earnings and Revenues Lag EstimatesNovember 8, 2022 | finance.yahoo.comWill Heska Corporation (HSKA) Overcome the Current Challenges?See More Headlines Receive HSKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter. Email Address HSKA Company Calendar Last Earnings11/04/2021Today9/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HSKA CUSIPN/A CIK1038133 Webwww.heska.com Phone(970) 493-7272Fax970-619-3003Employees808Year FoundedN/APrice Target and Rating Average Stock Price Forecast$137.25 High Stock Price Forecast$150.00 Low Stock Price Forecast$120.00 Forecasted Upside/Downside+14.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E Ratio266.64 P/E GrowthN/ANet Income$-19,890,000.00 Net Margins-7.86% Pretax Margin-7.91% Return on Equity0.94% Return on Assets0.67% Debt Debt-to-Equity Ratio0.23 Current Ratio5.64 Quick Ratio4.12 Sales & Book Value Annual Sales$257.31 million Price / Sales5.09 Cash Flow$1.69 per share Price / Cash Flow70.99 Book Value$39.00 per share Price / Book3.08Miscellaneous Outstanding Shares10,910,000Free Float9,572,000Market Cap$1.31 billion OptionableNot Optionable Beta1.58 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Kevin S. Wilson (Age 51)CEO, Pres & Director Comp: $988.17kMs. Catherine I. Grassman CPA (Age 47)Exec. VP & CFO Comp: $536.46kMr. Christopher D. Sveen (Age 40)EVP, Chief Admn. Officer, Gen. Counsel, Corp. Sec. & Pres of Diamond Animal Health Comp: $457.89kMr. Steven M. Eyl (Age 57)Exec. VP, Chief Commercial Officer & Pres of scil animal care company Comp: $475.28kMs. Eleanor F. Baker (Age 38)Exec. VP, MD & COO of Scil Animal Care Company Comp: $467.77kMr. Jon AagaardDirector of Investor RelationsMr. Anthony C. Providenti Jr. (Age 56)Exec. VP of Corp. Devel. Dr. Nancy Wisnewski Ph.D. (Age 60)Chief Science Advisor to CEO Daniel J. PollackVP of Imaging Operations, Treasurer & Assistant Sec.Cynthia PattersonVP of Customer CareMore ExecutivesKey CompetitorsNuVasiveNASDAQ:NUVASummit TherapeuticsNASDAQ:SMMTEstablishment LabsNASDAQ:ESTAArvinasNASDAQ:ARVNHims & Hers HealthNYSE:HIMSView All CompetitorsInsiders & InstitutionsEverence Capital Management Inc.Bought 1,950 shares on 7/14/2023Ownership: 0.018%Kevin S WilsonBought 11,018 shares on 1/6/2023Total: $645,875.16 ($58.62/share)Kevin S WilsonBought 3,440 shares on 12/22/2022Total: $205,161.60 ($59.64/share)View All Insider TransactionsView All Institutional Transactions HSKA Stock - Frequently Asked Questions Should I buy or sell Heska stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HSKA shares. View HSKA analyst ratings or view top-rated stocks. What is Heska's stock price forecast for 2023? 4 Wall Street analysts have issued 1-year target prices for Heska's shares. Their HSKA share price forecasts range from $120.00 to $150.00. On average, they anticipate the company's share price to reach $137.25 in the next twelve months. This suggests a possible upside of 14.4% from the stock's current price. View analysts price targets for HSKA or view top-rated stocks among Wall Street analysts. How were Heska's earnings last quarter? Heska Co. (NASDAQ:HSKA) posted its earnings results on Thursday, November, 4th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.23. The medical research company earned $60.24 million during the quarter, compared to the consensus estimate of $63.80 million. Heska had a positive trailing twelve-month return on equity of 0.94% and a negative net margin of 7.86%. The company's revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.25) earnings per share. What is Kevin S. Wilson's approval rating as Heska's CEO? 5 employees have rated Heska Chief Executive Officer Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among the company's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Heska own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK). What is Heska's stock symbol? Heska trades on the NASDAQ under the ticker symbol "HSKA." Who are Heska's major shareholders? Heska's stock is owned by a number of institutional and retail investors. Top institutional investors include Everence Capital Management Inc. (0.02%). Insiders that own company stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson. View institutional ownership trends. What is Heska's stock price today? One share of HSKA stock can currently be purchased for approximately $119.99. How much money does Heska make? Heska (NASDAQ:HSKA) has a market capitalization of $1.31 billion and generates $257.31 million in revenue each year. The medical research company earns $-19,890,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. How many employees does Heska have? The company employs 808 workers across the globe. How can I contact Heska? Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The official website for the company is www.heska.com. The medical research company can be reached via phone at (970) 493-7272, via email at investorrelations@heska.com, or via fax at 970-619-3003. This page (NASDAQ:HSKA) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heska Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.